Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/EJE-08-0756
European Journal of Endocrinology, Vol 160, Issue 2, 121-133
Copyright © 2009 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
EJE-08-0756v1
160/2/121    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seppälä, M
Right arrow Articles by Yeung, W S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seppälä, M
Right arrow Articles by Yeung, W S
REVIEW

Glycodelin in reproductive endocrinology and hormone-related cancer

M Seppälä1, H Koistinen1, R Koistinen1,2, L Hautala1,2, P C Chiu3 and W S Yeung3

Departments of1 , Clinical Chemistry2 Obstetrics and Gynaecology, University of Helsinki and Helsinki University Central Hospital, Biomedicum Helsinki, 4th Floor, Helsinki 00029 HUS, Finland3 Department of Obstetrics and Gynaecology, Queen Mary Hospital, University of Hong Kong, Pokulfam Road, Hong Kong, People's Republic of China

(Correspondence should be addressed to M Seppälä; Email: mseppala{at}welho.com)

Abstract

Glycodelin is an endocrine-regulated glycoprotein that has significant effects on immune cells, apoptosis, reproduction, cell adhesion, differentiation and cancer. In reproduction, glycodelin contributes to capacitation and immunoprotection of spermatozoa, and it modulates sperm–oocyte binding, acrosome reaction and implantation. In endocrine-related cancer, the differentiation inducing effects of glycodelin are accompanied by growth restriction of malignant cells, decreased expression of oncogenes, increased expression of tumour suppressor genes and morphological reversion of the malignant phenotype. This review features these properties and clinical connections, highlighting the role of glycosylation in biological actions.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 European Society of Endocrinology.